Altamira Therapeutics Ltd. (NASDAQ:CYTO) Short Interest Update

Altamira Therapeutics Ltd. (NASDAQ:CYTO) was the target of a significant increase in short interest in March. As of March 15th, there was short interest totalling 61,700 shares, an increase of 9.0% from the February 29th total of 56,600 shares. Currently, 3.9% of the shares of the company are sold short. Based on an average trading volume of 1,170,000 shares, the short-interest ratio is presently 0.1 days.

Altamira Therapeutics Stock Down 2.8 %

Shares of NASDAQ:CYTO traded down $0.06 during midday trading on Tuesday, hitting $2.05. The stock had a trading volume of 112,894 shares, compared to its average volume of 1,172,966. The stock has a 50 day moving average price of $1.92 and a two-hundred day moving average price of $3.36. Altamira Therapeutics has a 1 year low of $1.61 and a 1 year high of $52.00.

Institutional Trading of Altamira Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Citadel Advisors LLC purchased a new stake in Altamira Therapeutics during the second quarter worth about $47,000. BlackRock Inc. raised its position in Altamira Therapeutics by 84.2% during the first quarter. BlackRock Inc. now owns 61,603 shares of the company’s stock worth $67,000 after acquiring an additional 28,151 shares during the last quarter. Finally, Armistice Capital LLC acquired a new position in Altamira Therapeutics during the third quarter worth about $203,000. Hedge funds and other institutional investors own 1.91% of the company’s stock.

Altamira Therapeutics Company Profile

Altamira Therapeutics Ltd., a clinical-and commercial-stage biopharmaceutical company, engages in the development of therapeutics that address various unmet medical needs in Switzerland, the United States, Europe, and Australia. The company develops OligoPhore/SemaPhore, a platform for delivery of oligonucleotides, such as small interfering ribonucleic acid or messenger RNA into target cells.